ARTICLE | Emerging Company Profile
Kira: overcoming the complexities of complement
Emerging Company Profile: Kira debuts with Beddingfield as CEO, three programs slated to enter clinic over 18 months
November 13, 2020 3:50 AM UTC
Cross-border biotech Kira is developing therapeutics for complement-mediated cancer and inflammatory and autoimmune diseases that address the mechanistic and PK challenges of targeting the complement pathway.
Kira Pharmaceuticals Ltd. was founded in 2017 by Chairman, President and Head of R&D Wenru Song; SAB Chair Wenchao Song; and Head of China Operations Gonghua Pan. ...